Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | VHL | P40337 | 1/20 | 0.48 |
| ▸ | ELOC | Q15369 | 1/20 | 0.48 |
| ▸ | ELOB | Q15370 | 1/20 | 0.48 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | WNT3A | P56704 | 2/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27985278 | 0.84 | CYP1A2 (0.65) | CYP3A4CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL10280811 | 0.84 | CYP1A2 (0.61) | CYP3A4CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL16597413 | 0.82 | CYP3A4 (0.55) | CYP3A4CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL15729562 | 0.82 | CYP3A4 (0.55) | CYP3A4CYP1A2CYP2D6CYP19A1CYP2C9 | |
| Hydrochloric Acid SCHEMBL17091355 | 0.81 | CYP3A4 (0.54) | CYP3A4CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL30773841 | 0.80 | VHL (0.50) | CYP3A4CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL12988609 | 0.79 | CYP3A4 (0.56) | CYP3A4CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL2285981 | 0.79 | CYP1A2 (0.59) | CYP3A4CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL25192825 | 0.79 | VHL (0.48) | CYP3A4CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL24135102 | 0.78 | EGLN2 (0.44) | CYP3A4CYP1A2CYP2D6CYP19A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105593211-B | Indole and indazole derivatives | 豪夫迈·罗氏有限公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-3049391-B1 | INDOLE AND INDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-12-26 | — | — | EP | disclosed |
| EP-2921480-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-10-11 | — | — | EP | disclosed |
| EP-2921480-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-10-11 | — | — | EP | disclosed |
| US-9777005-B2 | Bicyclic heterocyclic compound containing a substituted pyrrole ring | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9777005-B2 | Bicyclic heterocyclic compound containing a substituted pyrrole ring | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9777005-B2 | Bicyclic heterocyclic compound containing a substituted pyrrole ring | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-9732086-B2 | — | — | 2017-08-15 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| WO-2014077401-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2014-05-22 | — | — | WO | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| US-5753682-A | Imidazole lipoxygenase inhibitors | PFIZER INC. (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0703913-B1 | IMIDAZOLES AS LIPOXYGENASE INHIBITORS | PFIZER (US) | 1997-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | CYP3A4 2625/4885CYP1A2 2190/4885CYP2D6 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.